Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT)

Fiona Gaughran*, Daniel Stahl, Khalida Ismail, Kathryn Greenwood, Zerrin Atakan, Poonam Gardner-Sood, Brendon Stubbs, David Hopkins, Anita Patel, John Lally, Philippa Lowe, Maurice Arbuthnot, Diana Orr, Sarah Corlett, Jonas Eberhard, Anthony S. David, Robin Murray, Shubulade Smith, on behalf of the IMPaCT Team, Bee HarriesSusan Moore, Stefania Bonaccorso, Anna Kolliakou, Conan O'Brien, Ali Featherman, Catherine Fung, Margaret Heslin, Keji Dalemo, Stella Anakwe-Umeh, Gill Todd, Manyara Mushore, Stanley Mutsatsa, Ruth Ohlsen, Oliver Howes, Evangelos Papanastasiou, Mohammad Firdosi, Hannah Sallis, Irene Sambath, Guilia Di Clemente, Josefine Breedvelt, Candice Joseph, Marta Di Forti, Adewale Odesanya, Dami Onagbesan, Philippa Case, Augustine Musa, Christine Dalton, Keerthana Rudhra, Janet Treasure, Caroline Murphy, Joanna Kelly

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)
256 Downloads (Pure)


Background: People with psychosis have a reduced life expectancy of 10-20years, largely due to cardiovascular disease. This trial aimed to determine the effectiveness of a modular health promotion intervention (IMPaCT Therapy) in improving health and reducing cardiovascular risk in psychosis. Methods: A multicentre, two arm, parallel cluster RCT was conducted across five UK mental health NHS trusts. Community care coordinators (CC) were randomly assigned to training and supervision in delivering IMPaCT Therapy or treatment as usual (TAU) to current patients with psychosis (cluster). The primary outcome was the physical and mental health subscales of the Short form-36 (SF-36) questionnaire. Results: Of 104 care coordinators recruited, 52 (with 213 patients) were randomised to deliver IMPaCT therapy and 52 (with 193 patients) randomised to TAU. Of 406 patients, 318 (78%) and 301 (74%) attended 12- and 15-month follow-up respectively. IMPaCT therapy showed no significant effect on the physical or mental health component SF-36 scores versus TAU at 12 or 15months. No effect was observed for cardiovascular risk indicators, except for HDL cholesterol, which improved more with IMPACT therapy than TAU (Treatment effect (95% CI); 0.085 (0.007 to 0.16); p= 0.034). The 22% of patients who received >180min of IMPACT Therapy in addition to usual care achieved a greater reduction in waist circumference than did controls, which was clinically significant. Conclusion: Training and supervising community care coordinators to use IMPaCT therapy in patients with psychosis is insufficient to significantly improve physical or mental health quality of life. The search for effective, pragmatic interventions deliverable in health care services continues. Trial registration: The trial was retrospectively registered with ISRCTN registry on 23/4/2010 at ISRCTN58667926 ; recruitment started on 01/03/2010 with first randomization on 09.08.2010 ISRCTN58667926.

Original languageEnglish
Article number413
Number of pages14
JournalBMC Psychiatry
Issue number1
Early online date28 Dec 2017
Publication statusPublished - 28 Dec 2017


  • Health promotion intervention
  • Mortality
  • Psychosis
  • Quality of life
  • Schizophrenia


Dive into the research topics of 'Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT)'. Together they form a unique fingerprint.

Cite this